<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02549352</url>
  </required_header>
  <id_info>
    <org_study_id>LP0084-1196</org_study_id>
    <nct_id>NCT02549352</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up</brief_title>
  <official_title>Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the trial is to compare the short term efficacy of LEO 43204 gel with
      vehicle gel in AK on the balding scalp when applied topically once daily for 3 consecutive
      days as field treatment
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">September 22, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Complete Clearance of Actinic Keratosis (AK)</measure>
    <time_frame>At Week 8</time_frame>
    <description>The number of clinically visible actinic keratosis lesions (AKs) identified in the treatment area was recorded at Day 1 (baseline), Weeks 4, and 8.
Complete clearance was defined as no clinically visible AKs in the treatment area.
The table shows the percentage of mean number of participants across imputations with complete clearance at Week 8.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Partial Clearance</measure>
    <time_frame>At Week 8</time_frame>
    <description>The number of clinically visible Actinic keratosis lesions (AKs) identified in the treatment area was recorded at Day 1, Weeks 4, and Week 8.
Partial clearance was defined as at least 75% reduction from baseline in the number of clinically visible AKs in the treatment area.
The table shows the percentage of mean number of participants across imputations with partial clearance at Week 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Partial Clearance</measure>
    <time_frame>At Week 4</time_frame>
    <description>The number of clinically visible Actinic keratosis lesions (AKs) identified in the treatment area was recorded at Day 1, Weeks 4, and Week 8.
Partial clearance was defined as at least 75% reduction from baseline in the number of clinically visible AKs in the treatment area.
The table shows the percentage of mean number of participants across imputations with partial clearance at Week 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Reduction in AK Count in the Treatment Area Compared to Baseline</measure>
    <time_frame>At Week 8</time_frame>
    <description>The percent reduction at Week 8 from baseline was analysed using a negative binomial regression for the AK count at Week 8 with treatment group and pooled sites as factors and baseline count as offset variable (using multiple imputations to account for missing values). The table presents adjusted mean percent reduction at Week 8 from baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">391</enrollment>
  <condition>Actinic Keratosis</condition>
  <arm_group>
    <arm_group_label>LEO 43204 gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment once daily for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treatment once daily for 3 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO43204 gel</intervention_name>
    <arm_group_label>LEO 43204 gel</arm_group_label>
    <other_name>Ingenol Disoxate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle gel</intervention_name>
    <arm_group_label>Vehicle gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with 5 to 20 clinically typical, visible and discrete AKs within a treatment
             area of sun-damaged skin on the full balding scalp (the balding part of the scalp
             should be greater than 25 cm2 (4 in2) and up to approximately 250 cm2 (40 In2)

          -  Subjects with minimum 3 clinically typical, visible and discrete AKs within a tracking
             area of 50 cm2 (8 In2). The tracking area must be within the treatment area

        Exclusion Criteria:

          -  Location of the treatment area (balding scalp) within 5 cm of an incompletely healed
             wound or within 5 cm of a suspected BCC or SCC

          -  Treatment with ingenol mebutate gel in the treatment area within the last 12 months

          -  Lesions in the treatment area that have: atypical clinical appearance (e.g.
             hyperthrophic, hyperkeratotic or cutaneous horns) and /or, recalcitrant disease (e.g.
             did not respond to cryotherapy on two previous occasions)

          -  History or evidence of skin conditions other than the trial indication that would
             interfere with the evaluation of the trial medication (e.g. eczema, unstable
             psoriasis, xeroderma pigmentosum)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rolf-Markus Szeimies, Prof. Dr.med</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinik für Dermatologie &amp; Allergologie Klinikum Vest GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinik für Dermatologie &amp; Allergologie Klinikum Vest GmbH</name>
      <address>
        <city>Recklinghausen</city>
        <zip>45657</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.leo-pharma.com/Home/Research-and-Development/Clinical-trial-disclosure/Clinical-trial-summaries-and-reports.aspx</url>
    <description>Related Info</description>
  </link>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>September 9, 2015</study_first_submitted>
  <study_first_submitted_qc>September 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2015</study_first_posted>
  <results_first_submitted>October 5, 2018</results_first_submitted>
  <results_first_submitted_qc>December 4, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">December 26, 2018</results_first_posted>
  <disposition_first_submitted>September 1, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>September 1, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">September 6, 2017</disposition_first_posted>
  <last_update_submitted>December 4, 2018</last_update_submitted>
  <last_update_submitted_qc>December 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis, Actinic</mesh_term>
    <mesh_term>Keratosis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>391 participants were enrolled, 80 were screening failures, and 311 participants were randomized. Only 310 of the randomized participants were treated with investigational medicinal product (IMP), the number of participants treated is reflected as the number of participants started in the first period.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>LEO 43204 0.037% Gel</title>
          <description>Treatment once daily with LEO 43204 0.037% gel for 3 consecutive days applied on the scalp.</description>
        </group>
        <group group_id="P2">
          <title>Vehicle Gel</title>
          <description>Treatment once daily with vehicle gel for 3 consecutive days applied on the scalp.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>3-day Treatment and 8-week Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="209"/>
                <participants group_id="P2" count="102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="209"/>
                <participants group_id="P2" count="101">1 participant was included in 0.037% in the safety analysis set as they received both IMPs in error</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="207"/>
                <participants group_id="P2" count="96"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>12-month Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="207"/>
                <participants group_id="P2" count="93"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="199"/>
                <participants group_id="P2" count="81"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>LEO 43204 0.037% Gel</title>
          <description>Treatment once daily with LEO 43204 0.037% gel for 3 consecutive days applied on the scalp.</description>
        </group>
        <group group_id="B2">
          <title>Vehicle Gel</title>
          <description>Treatment once daily with vehicle gel for 3 consecutive days applied on the scalp.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="209"/>
            <count group_id="B2" value="101"/>
            <count group_id="B3" value="310"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.7" spread="9.0"/>
                    <measurement group_id="B2" value="71.0" spread="9.3"/>
                    <measurement group_id="B3" value="70.1" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Age group</title>
              <category_list>
                <category>
                  <title>18-64 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
                <category>
                  <title>65-84 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="139"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="214"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=85 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="209"/>
                    <measurement group_id="B2" value="101"/>
                    <measurement group_id="B3" value="310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="141"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Complete Clearance of Actinic Keratosis (AK)</title>
        <description>The number of clinically visible actinic keratosis lesions (AKs) identified in the treatment area was recorded at Day 1 (baseline), Weeks 4, and 8.
Complete clearance was defined as no clinically visible AKs in the treatment area.
The table shows the percentage of mean number of participants across imputations with complete clearance at Week 8.</description>
        <time_frame>At Week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LEO 43204 0.037% Gel</title>
            <description>Treatment once daily with LEO 43204 0.037% gel for 3 consecutive days applied on the scalp.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Gel</title>
            <description>Treatment once daily with vehicle gel for 3 consecutive days applied on the scalp.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Complete Clearance of Actinic Keratosis (AK)</title>
          <description>The number of clinically visible actinic keratosis lesions (AKs) identified in the treatment area was recorded at Day 1 (baseline), Weeks 4, and 8.
Complete clearance was defined as no clinically visible AKs in the treatment area.
The table shows the percentage of mean number of participants across imputations with complete clearance at Week 8.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.0" lower_limit="16.4" upper_limit="27.7"/>
                    <measurement group_id="O2" value="3.0" lower_limit="-0.3" upper_limit="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mantel Haenszel</method>
            <param_type>Ratio of clearance rates</param_type>
            <param_value>7.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.58</ci_lower_limit>
            <ci_upper_limit>23.71</ci_upper_limit>
            <estimate_desc>Mantel-Haenszel estimate (0.037% relative to vehicle), adjusted for pooled sites.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Partial Clearance</title>
        <description>The number of clinically visible Actinic keratosis lesions (AKs) identified in the treatment area was recorded at Day 1, Weeks 4, and Week 8.
Partial clearance was defined as at least 75% reduction from baseline in the number of clinically visible AKs in the treatment area.
The table shows the percentage of mean number of participants across imputations with partial clearance at Week 8.</description>
        <time_frame>At Week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LEO 43204 0.037% Gel</title>
            <description>Treatment once daily with LEO 43204 0.037% gel for 3 consecutive days applied on the scalp.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Gel</title>
            <description>Treatment once daily with vehicle gel for 3 consecutive days applied on the scalp.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Partial Clearance</title>
          <description>The number of clinically visible Actinic keratosis lesions (AKs) identified in the treatment area was recorded at Day 1, Weeks 4, and Week 8.
Partial clearance was defined as at least 75% reduction from baseline in the number of clinically visible AKs in the treatment area.
The table shows the percentage of mean number of participants across imputations with partial clearance at Week 8.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.1" lower_limit="56.5" upper_limit="69.7"/>
                    <measurement group_id="O2" value="11.0" lower_limit="4.9" upper_limit="17.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The p-values for secondary endpoints have been corrected by the Holm-Bonferroni method to account for multiplicity. The prespecified multiplicity adjustment by the Holm-Bonferroni method requires the ordering of the p-values for the secondary endpoints by size.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mantel Haenszel</method>
            <param_type>Ratio of clearance rates</param_type>
            <param_value>5.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.32</ci_lower_limit>
            <ci_upper_limit>10.51</ci_upper_limit>
            <estimate_desc>Mantel-Haenszel estimate (0.037% relative to vehicle), adjusted for pooled sites.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Partial Clearance</title>
        <description>The number of clinically visible Actinic keratosis lesions (AKs) identified in the treatment area was recorded at Day 1, Weeks 4, and Week 8.
Partial clearance was defined as at least 75% reduction from baseline in the number of clinically visible AKs in the treatment area.
The table shows the percentage of mean number of participants across imputations with partial clearance at Week 4.</description>
        <time_frame>At Week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LEO 43204 0.037% Gel</title>
            <description>Treatment once daily with LEO 43204 0.037% gel for 3 consecutive days applied on the scalp.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Gel</title>
            <description>Treatment once daily with vehicle gel for 3 consecutive days applied on the scalp.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Partial Clearance</title>
          <description>The number of clinically visible Actinic keratosis lesions (AKs) identified in the treatment area was recorded at Day 1, Weeks 4, and Week 8.
Partial clearance was defined as at least 75% reduction from baseline in the number of clinically visible AKs in the treatment area.
The table shows the percentage of mean number of participants across imputations with partial clearance at Week 4.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.4" lower_limit="46.5" upper_limit="60.3"/>
                    <measurement group_id="O2" value="7.1" lower_limit="2.0" upper_limit="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The p-values for secondary endpoints have been corrected by the Holm-Bonferroni method to account for multiplicity. The prespecified multiplicity adjustment by the Holm-Bonferroni method requires the ordering of the p-values for the secondary endpoints by size.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mantel Haenszel</method>
            <param_type>Ratio of clearance rates</param_type>
            <param_value>7.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.70</ci_lower_limit>
            <ci_upper_limit>15.61</ci_upper_limit>
            <estimate_desc>Mantel-Haenszel estimate (0.037% relative to vehicle), adjusted for pooled sites.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Reduction in AK Count in the Treatment Area Compared to Baseline</title>
        <description>The percent reduction at Week 8 from baseline was analysed using a negative binomial regression for the AK count at Week 8 with treatment group and pooled sites as factors and baseline count as offset variable (using multiple imputations to account for missing values). The table presents adjusted mean percent reduction at Week 8 from baseline.</description>
        <time_frame>At Week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LEO 43204 0.037% Gel</title>
            <description>Treatment once daily with LEO 43204 0.037% gel for 3 consecutive days applied on the scalp.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Gel</title>
            <description>Treatment once daily with vehicle gel for 3 consecutive days applied on the scalp.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Reduction in AK Count in the Treatment Area Compared to Baseline</title>
          <description>The percent reduction at Week 8 from baseline was analysed using a negative binomial regression for the AK count at Week 8 with treatment group and pooled sites as factors and baseline count as offset variable (using multiple imputations to account for missing values). The table presents adjusted mean percent reduction at Week 8 from baseline.</description>
          <units>percentage of change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.0" lower_limit="70.6" upper_limit="77.1"/>
                    <measurement group_id="O2" value="13.7" lower_limit="0.2" upper_limit="25.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The p-values for secondary endpoints have been corrected by the Holm-Bonferroni method to account for multiplicity. The prespecified multiplicity adjustment by the Holm-Bonferroni method requires the ordering of the p-values for the secondary endpoints by size.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Negative binominal regression with treatment group and pooled site as factors and log baseline count as offset variable.</p_value_desc>
            <method>Mantel Haenszel</method>
            <param_type>Week 8 AK count ratio</param_type>
            <param_value>0.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.25</ci_lower_limit>
            <ci_upper_limit>0.36</ci_upper_limit>
            <estimate_desc>0.037% relative to vehicle.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment period including follow-up (from Day 1 to Week 8) and extended follow-up (from Week 8 up to Month 14)</time_frame>
      <desc>Adverse events presented in the table are investigator-reported terms. Adverse events of special interest within system organ class (SOC) Neoplasm benign, malignant and unspecified (incl cysts and polyps), were adjudicated by an Independent Adjudication Committee based on central biopsy review.
For further details on the adjudication outcomes, see link to the full report in section &quot;More information&quot;
Adverse events are reported with a &gt;=2% frequency threshold for the active treatment group.</desc>
      <group_list>
        <group group_id="E1">
          <title>LEO 43204 0.037% Gel</title>
          <description>Treatment once daily with LEO 43204 0.037% gel for 3 consecutive days applied on the scalp.</description>
        </group>
        <group group_id="E2">
          <title>Vehicle Gel</title>
          <description>Treatment once daily with vehicle gel for 3 consecutive days applied on the scalp.</description>
        </group>
        <group group_id="E3">
          <title>LEO 43204 0.037% Gel - Extended Follow-up</title>
          <description>Treatment once daily with LEO 43204 0.037% gel for 3 consecutive days applied on the scalp.</description>
        </group>
        <group group_id="E4">
          <title>Vehicle Gel - Extended Follow-up</title>
          <description>Treatment once daily with vehicle gel for 3 consecutive days applied on the scalp.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (18.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (18.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="146" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eyelid oedema</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Periorbital oedema</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site pain</sub_title>
                <counts group_id="E1" subjects_affected="118" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Application site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>LEO acknowledges the investigators right to publish the entire results of the study, irrespective of outcome. LEO retains the right to have any publication submitted to LEO for review. Investigators must undertake not to submit any part of their individual data for publication without the prior consent of LEO.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trial Disclosure Specialist</name_or_title>
      <organization>LEO Pharma A/S</organization>
      <email>disclosure@leo-pharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

